Advances in the Management of
Allergic Rhinitis and Chronic Idiopathic Urticaria
Release date: June 2008
Expiration date: June 30, 2009
Estimated time to complete activity: 1.0 hours
Target Audience
This activity has been designed to meet the educational needs of physicians involved in the care of patients with allergic rhinitis and chronic idiopathic urticaria.
Program Overview
Allergic rhinitis (AR) and chronic idiopathic urticaria (CIU) are two of the most common diseases in the United States. Although these conditions are not life-threatening, appropriate, effective treatment is essential to maintain patient quality of life and productivity at work or school. However, the clinical management of AR and CIU is difficult as both conditions are often misdiagnosed or underdiagnosed. This program will focus on enhancing accurate diagnosis of AR and CIU, promoting the appropriate use of pharmacotherapeutic options, and overcoming common treatment misconceptions.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the process of inflammation and its relationship to symptoms associated with AR and CIU
- Describe the anti-inflammatory and anti-pruritic efficacy and symptom reduction of conventional H1 receptor antagonists in the management of AR and CIU
- Compare the efficacy and safety profiles of novel H1 antagonists
- Outline how to implement an action plan for the management of AR and CIU
Faculty
Bradley E. Chipps, MD, FAAP, FAAAI, FCCP
Medical Director of Respiratory Therapy
Medical Director of Cystic Fibrosis Center
Sutter Medical Center
Associate Medical Director
Sutter Community Hospitals Sleep Center
Sacramento, California
F. Estelle R Simons, MD, FRCPC
Professor, Department of Pediatrics & Child Health
Professor, Department of Immunology
University of Manitoba
Winnipeg, Manitoba
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Integrity Continuing Education. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
PIM designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
PIM assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Bradley E. Chipps, MD, FAAP, FAAAI, FCCP
Consultant: AstraZeneca, Genentech, GlaxoSmithKline, MedPoint, Merck, Novartis, sanofi-aventis, Schering, Sepracor
Grants/Research Support: AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, sanofi-aventis, Schering, Sepracor
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Merck, MedPoint, Novartis, Pfizer, sanofi-aventis, Schering, Sepracor
F. Estelle R. Simons, MD, FRCPC
Consultant: EPAAC Study Scientific Board
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Steven A. Henry, MD No real or apparent conflicts of interest to report
Linda Graham, RN, MSN No real or apparent conflicts of interest to report
Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period June 2008 through June 30, 2009, participants must:
- Read the learning objectives and faculty disclosures
- Study the educational activity
- Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
- Complete the evaluation form
- Mail or fax the evaluation form with answer key to PIM
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within three weeks.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, Integrity Continuing Education, sanofi-aventis US, and UCB Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Integrity Continuing Education, or sanofi-aventis US, or UCB Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
